STOCK TITAN
  1. Home
  2. Sec-filings
  3. EBS
  4. [Form 4] Emergent BioSolutions Inc. Insider Trading Activity

Emergent BioSolutions (EBS) awards 100,111 RSUs to R&D CMO

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lowry Simon C reported acquisition or exercise transactions in this Form 4 filing.

Emergent BioSolutions Inc. granted SVP, R&D, CMO Simon C. Lowry 100,111 shares of common stock in the form of restricted stock units. The award was approved by the Compensation Committee on March 2, 2026 and became effective after stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming continued service. Each unit entitles Lowry to receive one share of common stock, bringing his direct holdings to 177,914 shares after the grant.

Positive

  • None.

Negative

  • None.
Insider Lowry Simon C
Role SVP, R&D, CMO
Type Security Shares Price Value
Grant/Award Common Stock 100,111 $0.00 --
Holdings After Transaction: Common Stock — 177,914 shares (Direct, null)
Footnotes (1)
  1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
RSUs granted 100,111 shares Restricted stock units awarded to Simon C. Lowry
Holdings after grant 177,914 shares Total direct common stock holdings following transaction
Committee approval date March 2, 2026 Compensation Committee approval of RSU grant
Stockholder approval date April 29, 2026 Stockholders approved Amended Stock Incentive Plan
Vesting schedule Three annual installments RSUs vest annually beginning on approval anniversary
restricted stock units financial
"Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Amended Stock Incentive Plan financial
"subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan")."
Compensation Committee financial
"The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc."
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
vest in three annual installments financial
"These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval,"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lowry Simon C
(Last)(First)(Middle)
300 PROFESSIONAL DRIVE
(Street)
GAITHERSBURG MARYLAND 20879
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, R&D, CMO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/29/202604/29/2026(1)A100,111(2)A$0177,914D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
2. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Remarks:
/s/ Richard S. Lindahl, Attorney-in-fact05/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Emergent BioSolutions (EBS) disclose in this Form 4 for Simon C. Lowry?

Emergent BioSolutions reported that SVP, R&D, CMO Simon C. Lowry received 100,111 restricted stock units. These awards are part of his equity compensation and increase his direct holdings to 177,914 common shares in the company.

How many restricted stock units did Simon C. Lowry receive from Emergent BioSolutions (EBS)?

Simon C. Lowry received 100,111 restricted stock units of Emergent BioSolutions common stock. Each unit represents the right to one share upon vesting, subject to the terms and adjustments outlined in the applicable grant agreement.

How and when do Simon C. Lowry’s Emergent BioSolutions (EBS) RSUs vest?

The restricted stock units vest in three annual installments, starting on the anniversary of the approval date. Vesting depends on Lowry’s continued service with Emergent BioSolutions, aligning his compensation with longer-term employment and company performance.

What approvals were required for Simon C. Lowry’s RSU grant at Emergent BioSolutions (EBS)?

The RSU grant was approved by the Compensation Committee on March 2, 2026, subject to stockholder approval of the Amended Stock Incentive Plan. Stockholders subsequently approved the plan on April 29, 2026, allowing the grant to take effect.

What is Simon C. Lowry’s total Emergent BioSolutions (EBS) share ownership after this RSU grant?

Following the RSU grant, Simon C. Lowry directly holds 177,914 shares of Emergent BioSolutions common stock. This figure includes the newly awarded restricted stock units reported in the Form 4 insider transaction filing.